What does the past generation of failure in Alzheimer’s R&D look like in one slide?
Just how bad is it in the Alzheimer’s R&D arena?
IQVIA just put together something of an impressionist piece on the slew of trial failures recorded over the years (below).
Except for one pop in 2014 — for a dementia drug, Namzaric — there’s nothing by way of an FDA approval going back to 2002, 17 years of failure and disaster, with Eli Lilly, Pfizer, J&J and others going over the amyloid beta cliff. That’s made the big players leery of this field, but the prospect of being the only significant therapy on the market for millions of patients continues to fuel the drive toward something — anything — to throw against the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
